Duchenne Muscular Dystrophy

Latest News

Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne

February 12th 2025

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is priced at $3.2 million per dose, produced $821 million in net product revenue for the company in 2024.

medical art of heart showing aorta, other blood vessels | ©abhijith3747 stock.adobe.com
Cumberland Pharmaceuticals Reports Promising Results Itetroban for DMD Patients

February 10th 2025

word inflammation w stethoscope in foreground | image credit: @cacaroot stock.adobe.com
Nonsteroidal Drug for Duchenne Launches with a $700,000 Price Tag

July 25th 2024

Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians

July 19th 2024

More News

© 2025 MJH Life Sciences

All rights reserved.